glp 1 weight loss medication side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists Weight loss drugs without the
Description
Its incredibly concerning that most prescribers are not screening for eating disorders before starting these medications

NEJM , U.S
Exclusive Pharma Industry 4 min read The Expiry of Ozempics Patent in 2026 Could Revolutionize Indias Battle Against Obesity Despite the rising burden of obesity-related illnessesranging from diabetes and cardiovascular diseases to metabolic disorderseffective pharmacological treatments like Ozempic remain out of reach for most Indians due to their prohibitive costs

Adipose tissue inflammation and metabolic dysfunction in obesity
